The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 10, 2025

Filed:

Dec. 20, 2019
Applicant:

Zhejiang Shimai Pharmaceutical Co., Ltd., Hangzhou, CN;

Inventors:

Weizao Chen, Frederick, MD (US);

Yanping Wang, Frederick, MD (US);

Zuoxiang Xiao, Frederick, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/46 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/71 (2006.01); C07K 14/82 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C07K 16/468 (2013.01); A61P 35/00 (2018.01); C07K 14/71 (2013.01); C07K 14/82 (2013.01); C07K 16/2809 (2013.01); C07K 16/2863 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/50 (2013.01);
Abstract

The present invention provides recombinant bispecific antibodies designed to bind to a surface antigen on target cells and to an activating component on immune cells such as T cells. The bispecific antibodies comprise two polypeptide chains that contain Fv and Fab as antigen¬binding fragments and a modified Fc region to facilitate heterodimer formation. In one embodiment, the bispecific antibodies further comprise protease cleavage sites and/or motifs that would cause steric occlusion of the antigen binding sites so that the antibodies would be activated only in a specific environment, e.g. in the vicinity of a tumor. In another embodiment, the bispecific antibodies comprise modified sequences that confer reduced binding affinity to CDS and/or cross-reactive binding to CDS on cells from different species.


Find Patent Forward Citations

Loading…